The University of Arizona has licensed new radio-labeling chemistry for PET contrast agents to startup TheraCea Pharma.
"Our advantage is that we've simplified the methods that allow non-experts to do the nuclear chemistry," said Daryaei, TheraCea Pharma co-founder and CEO. "We've done the work to make sure that it's useful and simple for any lab technician to use."
Part of what makes PET imaging work is that specific formulations containing small, safe amounts of a radioactive isotope are injected into the body as contrast agents. But making these agents, which commonly use the radioisotope Flourine-18, is no small task. Before the UArizona team's innovation, this required an expert in nuclear chemistry to work through the processes to bind Flourine-18 to diagnostic agents and produce a patient-ready formulation.